Article
Brochure
Executive Resource
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
Weaver’s transaction advisory team highlights a recent success guiding a client through a contentious net working capital and earn-out dispute.
Weaver supported an aviation management firm with sell-side financial and tax assistance, saving the client over $1 million in post-close adjustments.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Weaver’s Transaction Advisory Services team highlights a recent success story, guiding a client through an investment in a fast-casual restaurant.
Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.
Executive ResourceWhen a small to medium-sized business owner exits a company, the factors they need to ponder are varied and complex. Here’s an overview of those considerations.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.
With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
Whether preceding an M&A transaction or another executive hire, due diligence identifies any red flags before inking a high-stakes deal.
